Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PenumbraBSP:P2NB34 21 12-1 Month Momentum % is N/A% as of Sep. 05, 2026. GuruFocus rates BSP:P2NB34 with a GF Score™ of 21/100 and a GF Value™ of R$57.24 (Fairly Valued). The stock has 1 warning sign investors should review. Among 823 Medical Devices & Instruments companies, Penumbra ranks better than 83.84% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-05), Penumbra's 12-1 Month Momentum % is N/A%.
The industry rank for Penumbra's 12-1 Month Momentum % or its related term are showing as below:
BSP:P2NB34's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -18.64 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Penumbra (BSP:P2NB34) has a 12-1 Month Momentum % of N/A% as of Sep. 05, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Penumbra and its competitors. According to the industry distribution chart, Penumbra ranks #133 out of 823 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is Penumbra's 12-1 Month Momentum % too high?
Penumbra's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Penumbra ranks #133 out of 823 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Penumbra has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's 12-1 Month Momentum % compare to GMED and GKOS?
According to the Medical Devices & Instruments industry distribution chart, Penumbra ranks #133 out of 823 companies for 12-1 Month Momentum %. This places Penumbra in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Penumbra and its competitors. Penumbra's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (BSP:P2NB34) is currently considered Fairly Valued. The stock's GF Value™ is R$57.24, compared to a current price of R$55.13 — trading 3.7% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Penumbra's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Penumbra (BSP:P2NB34), the current 12-1 Month Momentum % is N/A% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (BSP:P2NB34) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of R$55.13 is trading 3.7% below its estimated GF Value™ of R$57.24.
GuruFocus considers Penumbra to be Fairly Valued.
Key valuation signals for BSP:P2NB34:
12-1 Month Momentum %: N/A%
GF Value™: R$57.24 vs. price of R$55.13 (3.7% below fair value)
No single metric tells the full story. See the BSP:P2NB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
21GF Score
Get the complete analysis for BSP:P2NB34
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:P2NB34 has been successfully added to your 
